Tazocin Intervention Study
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00478855|
Recruitment Status : Completed
First Posted : May 25, 2007
Last Update Posted : December 10, 2007
- To determine the value of using piperacillin/tazobactam in reducing the cases of extended spectrum beta lactamases (ESBL) producing E. coli or K. pneumoniae colonization and infection.
- To determine the acquisition rate of ESBL producing E. coli or K. pneumoniae, both pre-and post-intervention in the selected medical centers.
|Condition or disease||Intervention/treatment||Phase|
|Bacterial Infections||Drug: Tazocin (Piperacillin/Tazobactem)||Phase 4|
|Study Type :||Interventional (Clinical Trial)|
|Enrollment :||500 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Association of Antibiotic Utilization Measures and Control of ESBLs Producing Bacteria|
|Study Start Date :||September 2006|
|Actual Study Completion Date :||June 2007|
- The acquisition rate of ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months; post-intervention)
- The infection rate due to ESBL producing E. coli or K. pneumoniae at the end of phase I (pre-intervention) and phase II (last 3 months; post-intervention)
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00478855
|Peking, China, 100730|
|Study Director:||Medical Monitor||Wyeth is now a wholly owned subsidiary of Pfizer|